Abstract
The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson’s disease (PD) and Alzheimer’s diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets.
In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).
Keywords: Genome wide association study (GWAS), neurodegenerative diseases, pharmacogenomics, psychiatric disorders.
Current Molecular Medicine
Title:The Applications of Pharmacogenomics to Neurological Disorders
Volume: 14 Issue: 7
Author(s): C. Gilman, C. McSweeney and Y. Mao
Affiliation:
Keywords: Genome wide association study (GWAS), neurodegenerative diseases, pharmacogenomics, psychiatric disorders.
Abstract: The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson’s disease (PD) and Alzheimer’s diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets.
In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).
Export Options
About this article
Cite this article as:
Gilman C., McSweeney C. and Mao Y., The Applications of Pharmacogenomics to Neurological Disorders, Current Molecular Medicine 2014; 14 (7) . https://dx.doi.org/10.2174/1566524014666140811115900
DOI https://dx.doi.org/10.2174/1566524014666140811115900 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Sex Differences in Biomarkers for Predicting Cardiovascular and Coronary Events
Current Vascular Pharmacology Deciphering Role of Cytokines for Therapeutic Strategies Against Rheumatoid Arthritis
Current Drug Targets Endothelin and the Ischaemic Heart
Current Vascular Pharmacology Circulating MicroRNAs as Biomarkers for Inflammatory Diseases
MicroRNA High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science Capsaicin Sensitive-Sensory Nerves and Blood Pressure Regulation
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Taste and Hypertension in Humans: Targeting Cardiovascular Disease
Current Pharmaceutical Design Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design The Gut Microbiota and Lipid Metabolism: Implications for Human Health and Coronary Heart Disease
Current Medicinal Chemistry Antithrombotic Therapy for Transcatheter Valvular Interventions: A Revisit
Current Vascular Pharmacology Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews The Association between Serum Asymmetric Dimethylarginine and Coronary Atherosclerotic Plaque in an Asymptomatic Population
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chronic Inflammatory Disorders and Accelerated Atherosclerosis: Chronic Kidney Disease
Current Pharmaceutical Design Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Pathogenesis and Treatment Options
Current Vascular Pharmacology Polyphenols: A Diverse Class of Multi-Target Anti-HIV-1 Agents
Current Drug Metabolism Patent Selections
Recent Patents on Cardiovascular Drug Discovery Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Optimized Turmeric Extracts have Potent Anti-Amyloidogenic Effects
Current Alzheimer Research